Sign up United Kingdom
OptiBiotix Health plc (LON:OPTI)

OptiBiotix Health plc (LON:OPTI)

Share Price
95.00 p
7 (7.95 %)
Market Cap
£80.15 m
Proactive Investors - Run By Investors For Investors

OptiBiotix Health plc RNS Release

US product launch of LPLDL® at trade show

RNS Number : 8198O
OptiBiotix Health PLC
24 August 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

US product launch of LPLDL® at Supply Side West trade show

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans for a US launch of LPLDL®, its cholesterol and blood pressure lowering product, at Supply Side West in Las Vegas, on 27-28 September 2017. This follows the global manufacturing and supply agreement with Sacco S.r.l. ("Sacco") announced on 22 August 2017.


The Supply Side West tradeshow brings together more than 15,000 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries and is viewed as one of the world's leading trade fairs for the food and drinks industry.

OptiBiotix will co-exhibit with Sacco and will present new product concepts, as well as launching existing products containing its cholesterol reducing strain (LPLDL®) at the show, including:-

·      CholBiome®: a proprietary formulation containing LPLDL® to reduce cholesterol levels and blood pressure; and

·      CardioBiome®: a proprietary formulation containing LPLDL® to reduce a wide range of cardiovascular disease factors and improve long term heart health.

The US launch of LPLDL®, CholBiome® and CardioBiome® at Supply Side West is the first of a number of commercial steps taken to supply LPLDL® to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into final formulations and presentations for distribution and sale into the US market.


The US is one of the largest and fastest-growing probiotic markets in the world, with supplements alone accounting for US$2.06bn sales, with a projected 55% growth to US$3.3bn by 2021.  Discussions continue to progress with corporate partners for the manufacture and distribution of products containing LPLDL® in the European, Asian and other international markets.


Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has made significant progress in raising industry awareness of its LPLDL® strain. This has created a high level of interest in commercialising products containing LPLDL® as a component in higher value branded products in markets globally. Exhibiting at Supply Side West creates the opportunity to communicate with high-end decision makers in the US market with the potential to generate revenues for different formulations and presentations across numerous applications at multiple points in the value chain with US and international partners."


OptiBiotix and Sacco will be available at booth Q137.


For further information, please contact:


OptiBiotix Health plc

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner


finnCap (Broker)


Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke / Abigail Wayne (Corporate Broking)

Walbrook PR Ltd

                 Tel: 020 7933 8780 or [email protected]

Anna Dunphy

Mob: 07876 741 001



About OptiBiotix - 


OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.


The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 


OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.


This information is provided by RNS
The company news service from the London Stock Exchange

OptiBiotix Health plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use